Name | Number of supported studies | Average coverage | |
---|---|---|---|
B cell | 31 studies | 34% ± 15% | |
plasma cell | 22 studies | 44% ± 15% | |
memory B cell | 15 studies | 31% ± 16% | |
naive B cell | 14 studies | 34% ± 16% | |
IgG plasma cell | 10 studies | 53% ± 22% | |
IgA plasma cell | 9 studies | 56% ± 20% | |
plasmablast | 8 studies | 41% ± 13% | |
fibroblast | 6 studies | 30% ± 8% | |
T cell | 5 studies | 36% ± 18% | |
macrophage | 5 studies | 37% ± 20% | |
CD8-positive, alpha-beta T cell | 5 studies | 34% ± 14% | |
mast cell | 4 studies | 47% ± 32% | |
conventional dendritic cell | 4 studies | 45% ± 25% | |
gamma-delta T cell | 4 studies | 42% ± 20% | |
precursor B cell | 4 studies | 38% ± 17% | |
immature B cell | 4 studies | 41% ± 20% | |
IgM plasma cell | 4 studies | 53% ± 16% | |
dendritic cell | 3 studies | 24% ± 7% | |
monocyte | 3 studies | 36% ± 22% | |
natural killer cell | 3 studies | 50% ± 16% | |
endothelial cell | 3 studies | 29% ± 3% | |
endothelial cell of lymphatic vessel | 3 studies | 31% ± 11% | |
endothelial cell of artery | 3 studies | 28% ± 4% | |
plasmacytoid dendritic cell | 3 studies | 39% ± 9% | |
regulatory T cell | 3 studies | 29% ± 8% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
intestine | 3 studies | 48% ± 27% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 94% | 5698.75 | 545 / 578 | 85% | 2526.43 | 983 / 1155 |
stomach | 75% | 6439.89 | 270 / 359 | 70% | 1266.67 | 199 / 286 |
intestine | 56% | 9729.71 | 541 / 966 | 65% | 1048.41 | 344 / 527 |
breast | 50% | 2931.69 | 231 / 459 | 52% | 962.23 | 583 / 1118 |
spleen | 100% | 38491.77 | 241 / 241 | 0% | 0 | 0 / 0 |
bladder | 33% | 2431.38 | 7 / 21 | 52% | 854.05 | 263 / 504 |
peripheral blood | 85% | 5684.05 | 792 / 929 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 80% | 2956.16 | 36 / 45 |
liver | 61% | 928.34 | 138 / 226 | 17% | 246.36 | 68 / 406 |
esophagus | 26% | 835.34 | 375 / 1445 | 50% | 751.44 | 92 / 183 |
uterus | 25% | 410.66 | 43 / 170 | 49% | 951.71 | 227 / 459 |
pancreas | 15% | 182.00 | 49 / 328 | 57% | 791.57 | 102 / 178 |
kidney | 44% | 2088.56 | 39 / 89 | 25% | 404.36 | 221 / 901 |
thymus | 32% | 2902.17 | 211 / 653 | 35% | 812.61 | 210 / 605 |
lymph node | 0% | 0 | 0 / 0 | 62% | 1116.11 | 18 / 29 |
ovary | 21% | 292.45 | 37 / 180 | 39% | 715.97 | 167 / 430 |
skin | 7% | 86.67 | 122 / 1809 | 47% | 1167.34 | 221 / 472 |
prostate | 37% | 945.29 | 91 / 245 | 12% | 100.61 | 59 / 502 |
adipose | 29% | 766.33 | 346 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 22% | 694.54 | 295 / 1335 | 0% | 0 | 0 / 0 |
adrenal gland | 12% | 322.84 | 30 / 258 | 8% | 76.45 | 19 / 230 |
heart | 5% | 87.04 | 46 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 4% | 85.72 | 3 / 80 |
brain | 0% | 7.24 | 11 / 2642 | 2% | 13.64 | 12 / 705 |
muscle | 0% | 7.42 | 4 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0016064 | Biological process | immunoglobulin mediated immune response |
GO_0005615 | Cellular component | extracellular space |
GO_0071735 | Cellular component | IgG immunoglobulin complex |
GO_0072562 | Cellular component | blood microparticle |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005576 | Cellular component | extracellular region |
GO_0005886 | Cellular component | plasma membrane |
GO_0003823 | Molecular function | antigen binding |
Gene name | IGLC2 |
Protein name | Immunoglobulin lambda constant 2 (Ig lambda chain C region Kern) (Ig lambda chain C region NIG-64) (Ig lambda chain C region SH) (Ig lambda chain C region X) (Ig lambda-2 chain C region) |
Synonyms | |
Description | FUNCTION: Constant region of immunoglobulin light chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens . The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen . . |
Accessions | ENST00000390323.2 P0DOY2 |